» Articles » PMID: 21241732

Preclinical Evaluation of HIV-1 Therapeutic Ex Vivo Dendritic Cell Vaccines Expressing Consensus Gag Antigens and Conserved Gag Epitopes

Overview
Journal Vaccine
Date 2011 Jan 19
PMID 21241732
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dendritic cell (DC) therapy is a promising technology for the treatment of HIV infected individuals. HIV-1 Gag- and Nef RNA-loaded DC have previously been shown to induce immune responses ex vivo following coculture with autologous lymphocytes. However, polyfunctionality and memory responses following coculture have not been evaluated. In addition, little is known regarding whether specific HIV-1 proteome components, such as highly conserved regions of the HIV-1, could enhance clinical responses following DC therapy.

Methodology And Principal Findings: To determine the breadth of the immune responses to antigen loaded DC, we analyzed polyfunctional T cell response ex vivo to Gag RNA loaded DC. Blood samples were used to generate monocyte derived DC, which were then matured and cocultured with autologous lymphocytes. We found that cytokine-matured DC loaded with Gag RNA was able to induce Gag-specific IFN-γ and IL-2 responses after a 12-day coculture. We characterized these responses by polyfunctional intracellular cytokine staining and evaluation of T cell memory phenotypes. Central memory CD8+ T cells were induced ex vivo after DC coculture from each of 3 patients, and the effector memory pool was increased by DC coculture from 2 patients. We also observed a decrease in the terminal effector and intermediate CD8+ T cell pool and an increase in the naïve/other population. There was a reduction in terminal effector and intermediate CD4+ T cells, and a corresponding increase in naïve/other CD4+ T cells. Finally, we evaluated conserved regions of Gag as a novel DC therapy immunogen and found that a conserved element (CE) p24 Gag antigen elicited IFN-γ and IL-2 responses comparable to those induced by a full-length Gag antigen.

Conclusions: We showed that RNA-loaded DC therapy induced a polyfunctional T cell response ex vivo, supporting the use of such DC-therapy for HIV infection. However, the central and effector memory phenotypes of T cells did not appear to be enhanced during coculture with Gag RNA-loaded DC. Furthermore, comparable antigen-specific responses were induced in HIV infected individuals using full-length Gag or only conserved elements of the Gag p24 protein. This indicates that immune responses can be focused onto the conserved elements of Gag in the absence of other Gag components.

Citing Articles

Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119.

Kalams S, Felber B, Mullins J, Scott H, Allen M, De Rosa S JCI Insight. 2024; 9(18).

PMID: 39088271 PMC: 11466283. DOI: 10.1172/jci.insight.180819.


Efficient expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates.

Dross S, Venkataraman R, Patel S, Huang M, Bollard C, Rosati M Front Immunol. 2023; 14:1188018.

PMID: 37207227 PMC: 10189133. DOI: 10.3389/fimmu.2023.1188018.


HIV T-cell immunogen design and delivery.

Brander C, Hartigan-OConnor D Curr Opin HIV AIDS. 2022; 17(6):333-337.

PMID: 36165078 PMC: 9530002. DOI: 10.1097/COH.0000000000000765.


The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.

Mohamed H, Miller V, Jennings S, Wigdahl B, Krebs F J Immunol Res. 2020; 2020:9470102.

PMID: 32537473 PMC: 7267878. DOI: 10.1155/2020/9470102.


A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.

Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V J Transl Med. 2015; 13:60.

PMID: 25879820 PMC: 4336696. DOI: 10.1186/s12967-015-0392-5.


References
1.
Rousseau C, Lockhart D, Listgarten J, Maley S, Kadie C, Learn G . Rare HLA drive additional HIV evolution compared to more frequent alleles. AIDS Res Hum Retroviruses. 2009; 25(3):297-303. PMC: 2693345. DOI: 10.1089/aid.2008.0208. View

2.
Rinaldo C . Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med. 2008; 265(1):138-58. PMC: 2875880. DOI: 10.1111/j.1365-2796.2008.02047.x. View

3.
Mattapallil J, Douek D, Buckler-White A, Montefiori D, Letvin N, Nabel G . Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med. 2006; 203(6):1533-41. PMC: 2118314. DOI: 10.1084/jem.20060657. View

4.
Calarota S, Foli A, Maserati R, Baldanti F, Paolucci S, Young M . HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008; 180(9):5907-15. DOI: 10.4049/jimmunol.180.9.5907. View

5.
Buisson S, Benlahrech A, Gazzard B, Gotch F, Kelleher P, Patterson S . Monocyte-derived dendritic cells from HIV type 1-infected individuals show reduced ability to stimulate T cells and have altered production of interleukin (IL)-12 and IL-10. J Infect Dis. 2009; 199(12):1862-71. DOI: 10.1086/599122. View